This analysis examines clinical trial activity across RNA therapeutic classes, including small interfering RNA (siRNA), messenger RNA (mRNA), antisense oligonucleotides (ASO), aptamers, micro RNA (miRNA), self-amplifying RNA (saRNA), small-activating RNA (RNAa), and circular RNA (cirRNA).

It highlights key players in each segment and their role in advancing the RNA therapeutics landscape. It also explores intellectual property megatrends, along with major partnerships, collaborations, acquisitions, and funding activities driving growth.

• How fast is clinical development progressing across emerging segments and paving the way for growth?
• Which companies are leading innovation in RNA therapeutics and impacting future growth potential?
• Which growth opportunities are transforming the funding and partnership landscape?